Company Overview - Clearside Biomedical, Inc. is a biopharmaceutical company focused on revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS) [3] - The company utilizes a patented SCS Microinjector for targeted and compartmentalized delivery of therapies, aiming to improve patient outcomes in sight-threatening eye diseases [3] - Clearside's lead program, CLS-AX (axitinib injectable suspension), is in development for treating neovascular age-related macular degeneration (wet AMD), with planning for a Phase 3 program underway [3] Product Development - Clearside has developed its first product, XIPERE (triamcinolone acetonide injectable suspension), which is approved for suprachoroidal use and available in the U.S. through a commercial partner [3] - The company is also evaluating various small molecules for potential long-acting treatment of geographic atrophy (GA) [3] - Clearside strategically partners its SCS injection platform with other companies utilizing ophthalmic therapeutic innovations [3] Financial Information - The company will report its first quarter 2025 financial results on May 14, 2025, after the close of financial markets [1] - There will be no conference call hosted for this quarter [1]

Core Insights - Evogene Ltd. is set to release its financial results for Q1 2025 on May 21, 2025, followed by a conference call to discuss these results [1][2] Company Overview - Evogene Ltd. is a computational biology company that utilizes big data and artificial intelligence to innovate life-science product development, aiming to enhance success rates while minimizing development time and costs [3] - The company has established three unique technology engines: MicroBoost AI, ChemPass AI, and GeneRator AI, each focusing on different core components: microbes, small molecules, and genetic elements respectively [4] Subsidiaries and Focus Areas - Evogene operates four subsidiaries: 1. Biomica Ltd. focuses on microbiome-based therapeutics for human disorders using MicroBoost AI [6] 2. Lavie Bio Ltd. develops microbiome-based agricultural biologicals powered by MicroBoost AI [6] 3. AgPlenus Ltd. is engaged in developing next-generation agricultural chemicals for sustainable crop protection using ChemPass AI [6] 4. Casterra Ag Ltd. specializes in high-yield castor seed varieties for biofuel and other industries, utilizing GeneRator AI [6]

Core Insights - Apyx Medical Corporation reported a total revenue of $9.4 million for Q1 2025, a decrease from $10.2 million in the same period last year, primarily due to a significant drop in OEM revenue [5][7] - The Advanced Energy segment saw a 6% increase in revenue to $7.9 million, driven by strong sales of generator units and single-use handpieces [4][5] - The company is preparing to launch the AYON Body Contouring System in the second half of 2025, pending FDA clearance, which is expected to enhance its market position in surgical aesthetics [3][5] Financial Performance - Total revenue decreased by 8% year-over-year, with Advanced Energy revenue increasing by 6% while OEM revenue fell by 45% [5][7] - Gross profit for Q1 2025 was $5.7 million, with a gross profit margin of 60%, up from 58% in the prior year [8] - Operating expenses decreased significantly by $3.8 million to $8.7 million, reflecting cost-cutting measures implemented in the previous quarter [9] Loss and Adjusted EBITDA - The net loss attributable to stockholders decreased by 45% to $4.2 million, or $0.10 per share, compared to a loss of $7.6 million, or $0.22 per share, in Q1 2024 [11][20] - Adjusted EBITDA loss improved to $2.4 million from $5.3 million in the prior year, indicating better operational efficiency [11][26] Market Position and Strategy - Renuvion, the company's flagship product, was awarded the 2025 NewBeauty Award for "Best Minimally Invasive Skin Tightener," highlighting its growing recognition in the market [5][11] - The company aims to capitalize on the increasing demand for aesthetic procedures, particularly among patients using GLP-1 drugs for weight loss [3][5] - Apyx Medical's management expressed confidence in the company's path to profitability following recent restructuring and cost management efforts [6][9]

Core Insights - Ligand Pharmaceuticals reported a strong first quarter performance with total revenues of $45.3 million, a 46% increase from $31.0 million in the same period of 2024, driven by a 44% growth in royalty revenue [4][5] - The company reaffirmed its 2025 financial guidance, expecting total revenues between $180 million and $200 million, with adjusted earnings per diluted share projected to be between $6.00 and $6.25 [8][7] - Ligand's CEO highlighted the strength of the commercial royalty portfolio and the strategic transaction with Channel Therapeutics to accelerate the launch of ZELSUVMI, which is expected to create significant value for shareholders [3][9] Financial Performance - Total revenues for Q1 2025 were $45.3 million, with royalties contributing $27.5 million and Captisol sales at $13.5 million [4][5] - Research and development expenses surged to $50.1 million, primarily due to a one-time charge of $44.3 million related to a royalty financing agreement with Castle Creek Biosciences [4][5] - The GAAP net loss for Q1 2025 was $42.5 million, or $2.21 per share, compared to a net income of $86.1 million, or $4.75 per diluted share, in Q1 2024 [5][29] Strategic Transactions - Ligand announced a merger agreement with Channel Therapeutics, which will be supported by $50 million in capital from strategic investors [9][10] - The combined entity will focus on the commercialization of ZELSUVMI, the first FDA-approved prescription therapy for molluscum contagiosum infections [11][9] - Ligand's investment of $18 million in the combined company reflects its commitment to the growth of Pelthos Therapeutics [10][9] Portfolio Updates - Verona reported Ohtuvayre net sales of $71.3 million for Q1 2025, a 95% increase compared to the previous quarter [13] - Travere Therapeutics received European Commission approval for Filspari, enhancing its market position [14] - UroGen and Merck also reported significant advancements in their respective product pipelines, indicating a robust biopharmaceutical landscape [15][17] Cash Position - As of March 31, 2025, Ligand had cash, cash equivalents, and short-term investments totaling $208.9 million, including $24.2 million in Viking Therapeutics common stock [6][32]

BROOMFIELD, Colo., May 8, 2025 /PRNewswire/ -- Crocs, Inc. (NASDAQ: CROX), a world leader in innovative casual footwear for all, today announced its first quarter 2025 financial results."We are incredibly proud of our better-than-expected first quarter performance despite what has been an increasingly volatile macroeconomic backdrop since the onset of the year. Both our Crocs and HEYDUDE brands contributed to the outperformance with gross margins, operating margins, adjusted earnings per share, and cash flo ...

Financial Results - Warner Bros. Discovery, Inc. reported financial results for the quarter ended March 31, 2025 [1] - A conference call to discuss the results was scheduled for today at 8:30 a.m. ET [2] Conference Call Details - A telephone replay of the call will be available approximately two hours after the completion of the call until May 15, 2025 [3] - The replay can be accessed via phone using specific numbers and a passcode [3] Company Overview - Warner Bros. Discovery is a leading global media and entertainment company with a diverse portfolio of branded content across various platforms [4] - The company operates in over 220 countries and territories, offering content in 50 languages [4] - Key brands include Discovery Channel, Max, CNN, HBO, and many others [4]

Financial Performance - Company reported record first quarter revenue of $222.3 million, up 15.4% year-over-year, driven by double-digit organic growth in both residential and multi-family/commercial projects [1][6] - Single-family residential revenue increased to a first quarter record of $88.9 million, up 21.6% year-over-year [1][6] - Gross margin improved to 43.9%, up 510 basis points year-over-year [1][7] - Net income was $42.2 million, or $0.90 per diluted share, compared to $29.7 million, or $0.63 per diluted share, in the prior year quarter [1][9] - Adjusted net income was $43.1 million, or $0.92 per diluted share, compared to $30.9 million, or $0.66 per diluted share, in the prior year quarter [1][10] - Adjusted EBITDA was $70.2 million, up 37.5% year-over-year, representing 31.6% of total revenues [1][11] Cash Position and Capital Allocation - Company ended the first quarter with an all-time high cash position of $157.3 million and total liquidity of approximately $330 million [2][14] - Strong free cash flow of $28.8 million was generated during the quarter [1] - Company returned $7.0 million in cash dividends to shareholders [12][13] Strategic Developments - Company expanded its backlog by 24.9% year-over-year to a record $1.14 billion [2] - In April 2025, the company acquired Continental Glass Systems for approximately $30 million, enhancing its U.S. manufacturing capabilities [2][15] - Company is launching a feasibility analysis to develop automated manufacturing capabilities in the U.S. over the coming years [2] Market Outlook - Company updated its full year 2025 revenue guidance to a range of $960 million to $1.02 billion, representing growth of approximately 11% at the midpoint [2][17] - Adjusted EBITDA outlook narrowed to a range of $305 million to $330 million, representing growth of approximately 15% at the midpoint [2][17] - Company anticipates a full year 2025 impact of approximately $25 million associated with higher input costs and tariffs, which it expects to mitigate through pricing strategies and supply chain adjustments [2][17]

14 ALLY Robotic Laser Cataract Systems™ (“ALLY Systems”) placed in 1Q 2025 with an additional backlog of 24 systems pending installation as of March 31, 2025 34% Revenue growth over the first quarter 2024 and 22% Recurring revenue growth in the trailing twelve months Worldwide procedure volumes increased 33% over the first quarter of 2024 ORLANDO, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company), a global medical technology company focused on advanced robotic l ...

Core Insights - Cullinan Therapeutics has received approval from the European Medicines Agency (EMA) for CLN-978, with Phase 1 studies in rheumatoid arthritis and Sjögren's disease set to begin in Q2 2025 [1][6] - The company is advancing its clinical development of CLN-978 across multiple autoimmune diseases and expects to share initial clinical data in systemic lupus erythematosus (SLE) by the end of 2025 [2] - The pivotal Phase 2b study of zipalertinib has met its primary endpoint, with results to be presented at the 2025 ASCO Annual Meeting [3] Immunology - CLN-978 is being developed for systemic lupus erythematosus, rheumatoid arthritis, and Sjögren's disease, with ongoing Phase 1 studies in the U.S., Europe, and Australia [6] - The company plans to initiate a Phase 1 study for active, difficult-to-treat rheumatoid arthritis in Germany and Italy in Q2 2025 [6] - A Phase 1 study for active, moderate to severe Sjögren's disease is also set to begin in the U.S. in Q2 2025 [6] Oncology - The pivotal Phase 2b portion of the REZILIENT1 study of zipalertinib has met the primary endpoint of overall response rate in patients with EGFR ex20ins NSCLC [3][6] - The company plans to submit a New Drug Application (NDA) for relapsed/refractory EGFR ex20ins NSCLC in the second half of 2025 [6] - Development of CLN-619 in gynecological cancers has been discontinued due to preliminary results not meeting internal advancement thresholds [6] Financial Performance - As of March 31, 2025, the company reported cash and investments totaling $567.4 million, providing a runway into 2028 [3][11] - Research and development expenses for Q1 2025 were $41.5 million, up from $30.6 million in Q1 2024 [11][14] - The net loss attributable to Cullinan for Q1 2025 was $48.5 million, compared to $37.1 million for the same period in 2024 [11][14]

BROOKFIELD, NEWS, May 08, 2025 (GLOBE NEWSWIRE) -- Brookfield Wealth Solutions (NYSE, TSX: BNT) today announced financial results for the three months ended March 31, 2025. Sachin Shah, CEO of Brookfield Wealth Solutions, stated, “Our business is off to a strong start in 2025. We have entered the U.K. market and begun offering new products that expand our asset base while maintaining our fundamental objective of generating high-quality earnings and durable risk-adjusted returns within our business.” Unaudit ...